Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Core Viewpoint - Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has filed four novel patent applications for its candidates EL-22 and EL-32, targeting both the animal market and muscle loss treatment in obese patients, either as standalone therapies or in combination with GLP-1 receptor agonists [1][2][3]. Patent Applications - The four patent applications filed include compositions for treating sarcopenia and muscle loss in both humans and animals, emphasizing the engineered probiotic platform aimed at obesity care [2][5]. - The patents cover various formulations, including a fusion protein of Myo-2 for treating muscle loss in obese patients and animal feed additives to encourage muscle growth [4][5]. Intellectual Property Portfolio - Northstrive's patent portfolio now consists of 8 patent applications and 5 issued patents, providing protection in key markets such as the USA, Japan, China, and Korea [3][4]. - The newly filed patents are expected to strengthen the company's intellectual property position as it seeks to transform obesity care standards and enter the animal health market [3][4]. Company Overview - Northstrive Biosciences Inc. focuses on developing innovative solutions for obesity, particularly through preserving muscle mass during weight loss treatments [7]. - PMGC Holdings Inc. manages a diversified portfolio through strategic acquisitions and investments across various industries, including biopharmaceuticals [8].